The identified E2F1–ASH1L-AS1/APPLE–ERK1/2 signaling axis provides new insights into HCC pathogenesis and represents a promising target for precision therapy, though further validation in clinical cohorts and preclinical studies is needed. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.